AstraZeneca’s board has disclosed that CEO Pascal Soriot’s realized compensation for 2025 reached 17.7 million pounds ($23.9 million). This represents a 6.4% increase from the previous year, reflecting strong financial performance and a rise in the company’s share price despite a year characterized by significant global geopolitical uncertainty.
The majority of Soriot’s earnings stemmed from long-term incentive awards for the 2023-2025 cycle. While AstraZeneca delivered an impressive $58.7 billion in revenue, the CEO narrowly missed the maximum possible payout as the company’s total shareholder return (TSR) ranked sixth among a peer group of 18 pharmaceutical firms. Beyond financial metrics, Soriot was credited for securing “groundbreaking agreements,” including a drug-pricing deal with the U.S. administration and a $15 billion investment pledge in China through 2030.
The year 2026 is expected to be a critical period for validating AstraZeneca’s ambitious goal of reaching $80 billion in annual revenue by 2030. With over 20 anticipated late-stage clinical trial readouts, investors will gain more clarity on the feasibility of the long-term growth targets set by the chief executive.